XDx Inc., a South San Francisco-based molecular diagnostics company that develops tests for the monitoring of transplant rejection and autoimmune diseases, has withdrawn its registration for an $86.25 million IPO. No reason was given. The company had planned to trade on the Nasdaq, with JPMorgan and Morgan Stanley serving as co-lead underwriters.
XDx has raised over $86 million in VC funding, from firms like Kleiner Perkins Caufield & Byers, TPG Ventures, Sprout Group, Burrill & Co., DAG Ventures, Integral Capital Partners and Intel Capital. www.xdx.com